Citius Oncology, Inc. · NASDAQ:CTOR
Citius Oncology — Investor Presentation (December 2025)
19 slides from Citius Oncology's investor presentation, Dec 1, 2025
Slide 1: Corporate Overview December 2025
CORPORATE OVERVIEW NASDAQ: CTOR DECEMBER 2025
Slide 2: Forward Looking Language
FORWARD LOOKING LANGUAGE NASDAQ: CTOR | 2 This presentation has been prepared by Citius Oncology, Inc . (the “Company”) for informational purposes only and not for any other purpose . Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by
Slide 3: About Citius Oncology, Inc.
ABOUT CITIUS ONCOLOGY, INC. Biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies • NASDAQ: CTOR | Stand - alone public company since August 2024 • Majority - owned (~79%) subsidiary of Citius Pharmaceuticals (NASDAQ: CTXR) • Shared management ser
Slide 4: LYMPHIR Now Commercially Available in the U.S.
INDICATION: LYMPHIR is an IL2 - receptor - directed cytotoxin indicated for the treatment of adult patients with relapsed or refractory Stage I - III cutaneous T - cell lymphoma (CTCL) after at least one prior systemic therapy • First marketed product by Citius Oncology • Commercial supply shipped t
Slide 5: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM Shared management services agreement with Citius Pharmaceuticals mitigates execution risk, maximizes capital efficiency and leverages industry expertise LEONARD MAZUR CHAIRMAN & CEO JAIME BARTUSHAK EVP, CFO & CBO DR. MYRON CZUCZMAN EVP, CHIEF MEDICAL OFFICER OMAR LANSARI
Slide 6: What Is Cutaneous T-Cell Lymphoma (CTCL)?
WHAT IS CUTANEOUS T - CELL LYMPHOMA (CTCL)? • Orphan cancer • Severe quality - of - life impact: pain, pruritus, skin lesions • Patients with persistent or recurrent CTCL require systemic therapy • Limited systemic treatment options Considered to be incurable, CTCL is a Subgroup of Non - Hodgkin Lym
Slide 7: CTCL Patients Have a High Disease Burden
CTCL PATIENTS HAVE A HIGH DISEASE BURDEN T1 T4 Sézary cell T2 T3 Zackheim. J Am Acad Dermatol. 1999;40:418. Slide credit: clinicaloptions.com NASDAQ: CTOR | 7
Slide 8: Differentiated Mechanism of Action (MOA)
DIFFERENTIATED MECHANISM OF ACTION (MOA) LYMPHIR targets the IL - 2 receptor, working both as a targeted therapy against malignant T - cells AND as an immunotherapy against Tregs IL - 2 receptor offers a unique treatment opportunity in CTCL Malignant T - cells and Tregs share a common marker: the IL
Slide 9: Compelling Clinical Data
COMPELLING CLINICAL DATA NASDAQ: CTOR | 9 LYMPHIR addresses CTCL’s heavy Quality of Life burden 1. Objective Response is Complete Response and Partial Response according to the ISCL/EORTC Global Response Score. 2. In the Primary Efficacy Analysis set, 84.4% (54/64) of skin evaluable subjects had a d
Slide 10: Demonstrated Safety
DEMONSTRATED SAFETY Overall, LYMPHIR was well - tolerated with the use of pre - medications, close patient monitoring, and prompt initiation of supportive measures and drug management • No evidence of cumulative toxicity • Most patients experienced grade 1/2 treatment emergent adverse events (TEAEs)
Slide 11: Opportunities for Growth Beyond CTCL
OPPORTUNITIES FOR GROWTH BEYOND CTCL • University of Pittsburgh: an investigator - initiated trial is underway to evaluate LYMPHIR for potential use as an immuno - oncology therapy in combination with KEYTRUDA® in patients with recurrent or metastatic solid tumors (NCT05200559) • Encouraging prelimi
Slide 12: LYMPHIR Is Competitively Positioned
LYMPHIR IS COMPETITIVELY POSITIONED NASDAQ: CTOR | 12 Only FDA - Approved IL - 2 Receptor - Directed Therapy for CTCL • Novel mechanism : fusion protein targets IL - 2 receptors • Direct tumoricidal effect and transient T - reg depletion • Unique among systemic therapies • Patients are put on multip
Slide 13: Competitive Differentiation
COMPETITIVE DIFFERENTIATION Today’s CTCL treatments are non - curative LYMPHIR excels where current therapies are limited • Requires CD30+ biomarker • Peripheral neuropathy may limit use • Most effective in SS subsegment of CTCL (<5%) • Acts on blood disease rather than skin disease • ORR 21% in MF
Slide 14: Commercial Infrastructure: Distribution and Channel Access
COMMERCIAL INFRASTRUCTURE: DISTRIBUTION AND CHANNEL ACCESS 14 Patient - centric distribution strategy aims to promote timely product availability for eligible CTCL patients across all care settings • U.S. nationwide specialty distribution network fully operational • Cencora, Cardinal Health, and McK
Slide 15: Concentrated Prescriber Base
CONCENTRATED PRESCRIBER BASE NASDAQ: CTOR | 15 10% of Providers (Physicians) Treat ≥3 Patients 90 17 7 15 12 0 10 20 30 40 50 60 70 Number of Accounts 80 90 100 20 - 40 41 - 60 61 - 80 81 - 120 121 - 475 Number of Patients Accounts by Number of Diagnosed Patients Source: IQVIA Medical (Dx) & Pharmac
Slide 16: Patient and HCPs Clustered Near Major Cancer Centers
PATIENT AND HCPS CLUSTERED NEAR MAJOR CANCER CENTERS • Concentration of providers and accounts allows for a focused field force approach (~ 25 reps) • AI - driven targeting system enables identification of key treatment patterns, personalization of provider engagement, and more efficient allocation
Slide 17: Provider & Patient Support
PROVIDER & PATIENT SUPPORT Citius Oncology Access & Education Tools • HCP portal: www.lymphirhcp.com • Reimbursement and prior authorization support • Patient assistance via Citius Advantage program • Comprehensive education & prescribing tools NASDAQ: CTOR | 17
Slide 18: Multi-Layered Protection: Barriers to Entry
MULTI - LAYERED PROTECTION: BARRIERS TO ENTRY 12 years of BLA exclusivity Orphan Drug Exclusivity (7 years) ODD designation granted for CTCL and PTCL (CTCL exclusivity determined upon BLA review) Complex Proprietary Manufacturing Process trade secret 2 Patents Pending LYMPHIR use as combination ther
Slide 19: Why CTOR? Why Now?
WHY CTOR? WHY NOW? LYMPHIR is poised for successful launch with potential upside opportunities beyond CTCL • LYMPHIR is the only IL - 2R targeted therapy for CTCL • FDA - approved treatment in a rare cancer indication with no curative therapies • Commercial U.S. launch: December 2025 • Estimated $40
Citius Oncology — Investor Presentation (December 2025) on 6ix